315 related articles for article (PubMed ID: 21087119)
1. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Ainsworth MA
Scand J Gastroenterol; 2011 Mar; 46(3):310-8. PubMed ID: 21087119
[TBL] [Abstract][Full Text] [Related]
2. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
Steenholdt C
Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
[TBL] [Abstract][Full Text] [Related]
3. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
Maser EA; Villela R; Silverberg MS; Greenberg GR
Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
[TBL] [Abstract][Full Text] [Related]
4. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease.
Ainsworth MA; Bendtzen K; Brynskov J
Am J Gastroenterol; 2008 Apr; 103(4):944-8. PubMed ID: 18028512
[TBL] [Abstract][Full Text] [Related]
6. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease.
Imaeda H; Andoh A; Fujiyama Y
J Gastroenterol; 2012 Feb; 47(2):136-43. PubMed ID: 21953314
[TBL] [Abstract][Full Text] [Related]
7. Antibody response to infliximab and its impact on pharmacokinetics can be transient.
Vande Casteele N; Gils A; Singh S; Ohrmund L; Hauenstein S; Rutgeerts P; Vermeire S
Am J Gastroenterol; 2013 Jun; 108(6):962-71. PubMed ID: 23419382
[TBL] [Abstract][Full Text] [Related]
8. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.
Marits P; Landucci L; Sundin U; Davidsdottir L; Nilsson J; Befrits R; Wikström AC; Eberhardson M
J Crohns Colitis; 2014 Aug; 8(8):881-9. PubMed ID: 24486178
[TBL] [Abstract][Full Text] [Related]
9. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.
Ungar B; Chowers Y; Yavzori M; Picard O; Fudim E; Har-Noy O; Kopylov U; Eliakim R; Ben-Horin S;
Gut; 2014 Aug; 63(8):1258-64. PubMed ID: 24041539
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
Bond A; Asher R; Jackson R; Sager K; Martin K; Kneebone A; Philips S; Taylor W; Subramanian S
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):271-6. PubMed ID: 26657455
[TBL] [Abstract][Full Text] [Related]
11. Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD.
Zitomersky NL; Atkinson BJ; Fournier K; Mitchell PD; Stern JB; Butler MC; Ashworth L; Hauenstein S; Heiner L; Chuang E; Singh S; Bousvaros A
Inflamm Bowel Dis; 2015 Feb; 21(2):307-14. PubMed ID: 25569737
[TBL] [Abstract][Full Text] [Related]
12. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
Karmiris K; Paintaud G; Noman M; Magdelaine-Beuzelin C; Ferrante M; Degenne D; Claes K; Coopman T; Van Schuerbeek N; Van Assche G; Vermeire S; Rutgeerts P
Gastroenterology; 2009 Nov; 137(5):1628-40. PubMed ID: 19664627
[TBL] [Abstract][Full Text] [Related]
13. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
14. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
15. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease.
Candon S; Mosca A; Ruemmele F; Goulet O; Chatenoud L; Cézard JP
Clin Immunol; 2006 Jan; 118(1):11-9. PubMed ID: 16125467
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of infliximab: how to handle the problem?
Baert F; De Vos M; Louis E; Vermeire S;
Acta Gastroenterol Belg; 2007; 70(2):163-70. PubMed ID: 17715629
[TBL] [Abstract][Full Text] [Related]
17. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
Bortlik M; Duricova D; Malickova K; Machkova N; Bouzkova E; Hrdlicka L; Komarek A; Lukas M
J Crohns Colitis; 2013 Oct; 7(9):736-43. PubMed ID: 23200919
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
19. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
20. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features.
Annese V; Piepoli A; Perri F; Lombardi G; Latiano A; Napolitano G; Corritore G; Vandewalle P; Poulain D; Colombel JF; Andriulli A
Aliment Pharmacol Ther; 2004 Nov; 20(10):1143-52. PubMed ID: 15569117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
